PLRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
25.7M
+7.9%
23.9M
+9.6%
21.8M
-7.7%
23.6M
-16.6%
28.3M
R&D
17.9M
+7.2%
16.7M
+23.1%
13.6M
-12.8%
15.6M
-13.1%
17.9M
SG&A
7.8M
+9.5%
7.1M
-12.9%
8.2M
+2.5%
8.0M
-22.6%
10.3M
Operating Income
-25742000
-7.9%
-23862000
-9.6%
-21772000
+7.7%
-23577000
+16.6%
-28269000
EBITDA
-25510000
-8.0%
-23613000
-9.8%
-21508000
+7.3%
-23212000
+16.6%
-27833000
Net Income
-24377000
-9.0%
-22371000
-11.6%
-20040000
+15.0%
-23577000
+10.4%
-26301000
EPS (Basic)
$-0.39
-8.3%
$-0.36
-12.5%
$-0.32
+15.8%
$-0.38
+11.6%
$-0.43
EPS (Diluted)
$-0.39
-8.3%
$-0.36
-12.5%
$-0.32
+15.8%
$-0.38
+11.6%
$-0.43
Shares (Diluted)
61.9M
+0.0%
61.9M
+0.2%
61.8M
+0.6%
61.5M
+0.1%
61.4M
Pliant Therapeutics (PLRX) — Financials